RxDoctor Payments Data

Matthew Daka, MD

Interventional Cardiology · Fayetteville, NCNPI 1598985715

Payments from drug & device makers

$16,064in general payments, 2019–2025

Across 173 payments — averaging $92.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$10K
  • Cardiovascular Systems Inc.$1K
  • Edwards Lifesciences$1K
  • E.r. Squibb & Sons, L.L.C.$492
  • Baxter Healthcare$308
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$276
  • plus $2K from 34 others

What the payments were for

  • Travel & lodging$2,08613%
  • Food & beverage$3,96325%
  • Entertainment$140%
  • Other$10,00062%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,064 in reported general payments places this provider in the 55th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$429,071
Medicare patients
578
Services billed
4,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$357,269
EntrestoSacubitril/Valsartan101$118,887
XareltoRivaroxaban104$84,724
JardianceEmpagliflozin78$74,389
Ranolazine ErRanolazine306$30,171
BrilintaTicagrelor27$29,414
FarxigaDapagliflozin Propanediol20$18,974
Repatha SyringeEvolocumab25$13,528
Isosorbide Dinitrate318$11,837
Metoprolol Succinate707$7,020
Dofetilide18$6,906
Atorvastatin Calcium326$4,202
Eplerenone71$3,996
Carvedilol202$1,764
ClopidogrelClopidogrel Bisulfate162$1,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$357,269342 claims
NovartisEntresto$127$118,887101 claims
Johnson & JohnsonXarelto$175$84,724104 claims
Boehringer IngelheimJardiance$35$74,38978 claims
AstraZenecaBrilinta, Farxiga$15$48,38947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →